366 related articles for article (PubMed ID: 31671026)
21. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
Fang H; Huang D; Yang F; Guan X
Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
[TBL] [Abstract][Full Text] [Related]
22. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.
Zhang H; Wang J; Li J; Zhou X; Yin L; Wang Y; Gu Y; Niu X; Yang Y; Ji H; Zhang Q
Cancer Sci; 2021 Apr; 112(4):1603-1613. PubMed ID: 33453094
[TBL] [Abstract][Full Text] [Related]
23. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
24. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
Rossi L; McCartney A; Risi E; De Santo I; Migliaccio I; Malorni L; Biganzoli L; Di Leo A
Clin Breast Cancer; 2019 Dec; 19(6):392-398. PubMed ID: 31358432
[TBL] [Abstract][Full Text] [Related]
26. Clinical development of CDK4/6 inhibitor for breast cancer.
Iwata H
Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
[TBL] [Abstract][Full Text] [Related]
27. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
[TBL] [Abstract][Full Text] [Related]
28. Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Piezzo M; Chiodini P; Riemma M; Cocco S; Caputo R; Cianniello D; Di Gioia G; Di Lauro V; Rella FD; Fusco G; Iodice G; Nuzzo F; Pacilio C; Pensabene M; De Laurentiis M
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899139
[TBL] [Abstract][Full Text] [Related]
29. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
[TBL] [Abstract][Full Text] [Related]
30. The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials.
Huang T; He Y; Yu C; Mao F; Si Y
Endokrynol Pol; 2023; 74(1):89-105. PubMed ID: 36704980
[TBL] [Abstract][Full Text] [Related]
31. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials.
Munzone E; Pagan E; Bagnardi V; Montagna E; Cancello G; Dellapasqua S; Iorfida M; Mazza M; Colleoni M
ESMO Open; 2021 Dec; 6(6):100332. PubMed ID: 34864350
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
[TBL] [Abstract][Full Text] [Related]
33. CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Agostinetto E; Debien V; Marta GN; Lambertini M; Piccart-Gebhart M; de Azambuja E
Eur J Clin Invest; 2021 Jul; 51(7):e13535. PubMed ID: 33662161
[TBL] [Abstract][Full Text] [Related]
34. CDK4/6 Inhibitors for Advanced Hormone Receptor-Positive Breast Cancer, 2019 and Beyond.
Layman RM
J Natl Compr Canc Netw; 2019 Feb; 17(2):190-192. PubMed ID: 30787131
[No Abstract] [Full Text] [Related]
35. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Owsley J; Jimeno A; Diamond JR
Drugs Today (Barc); 2016 Feb; 52(2):119-29. PubMed ID: 27092341
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
37. CDK4/6 inhibitors in breast cancer.
Dukelow T; Kishan D; Khasraw M; Murphy CG
Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
[TBL] [Abstract][Full Text] [Related]
38. Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.
Scheidemann ER; Shajahan-Haq AN
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830174
[TBL] [Abstract][Full Text] [Related]
39. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Thein KZ; Htut TW; Ball S; Swarup S; Sultan A; Oo TH
Breast Cancer Res Treat; 2020 Sep; 183(2):479-487. PubMed ID: 32647939
[TBL] [Abstract][Full Text] [Related]
40. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer.
Portman N; Alexandrou S; Carson E; Wang S; Lim E; Caldon CE
Endocr Relat Cancer; 2019 Jan; 26(1):R15-R30. PubMed ID: 30389903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
